You are here

  • Home
  • Archive
  • Volume 7, Issue 4
  • Rofecoxib, 25 mg/day, was more effective than rofecoxib, 12.5 mg/day, celecoxib, or acetaminophen in osteoarthritis of the knee

Article Text

Article menu
Download PDFPDF
Therapeutics
Rofecoxib, 25 mg/day, was more effective than rofecoxib, 12.5 mg/day, celecoxib, or acetaminophen in osteoarthritis of the knee

https://doi.org/10.1136/ebm.7.4.123

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) JAMA 287, 64; Geba GP, Weaver AL, Polis AB, et al, for the VACT Group.. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. A randomized trial.. Jan 2;. :. –71.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with symptomatic osteoarthritis (OA) of the knee, are rofecoxib, celecoxib, and acetaminophen effective and safe?

    Design

    Randomised {allocation concealed*}†, blinded {clinicians, patients, data collectors and analysts, and outcome assessors}†,* controlled trial with 6 weeks of follow up.

    Setting

    29 clinical centres in the USA.

    Patients

    382 patients ≥ 40 years of age (mean age 63 y, 68% women) who had symptomatic OA of the knee for ≥ 6 months (American College of Rheumatology criteria and functional class rating of I, II, or III), used non-steroidal anti-inflammatory drugs (NSAIDs) or high dose acetaminophen for ≥ 30 days before study entry, and met relevant entry criteria based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (a visual analogue scale [VAS] ranging from 0 [best] to 100 …

    View Full Text

    Footnotes

    • Source of funding: Merck & Co, Inc.

    • For correspondence: Dr G P Geba, Merck & Co Inc, West Point, Philadelphia, USA. gregory_geba{at}merck.com.

    • ↵* See glossary.

    • ↵† Information provided by author.